1-800-710-4674

Blog Post

Return to News

Feature Story

 
aspirin and cancer

Can aspirin help treat cancer?

Comments from D. Randolph Drosick, M.D., medical oncologist and hematologist with OHC. Article by Ana Sandoiu, Medical News Today, Blogs, 0 comments
October 8, 2018

 
Drosick-David-R-MD-2017 OHC

D. Randolph Drosick, M.D., medical oncologist and hematologist with OHC

More and more studies are pointing to the benefits of adding aspirin to conventional cancer treatment. A new review examines this available research and asks the question: is it “time to share [the] evidence and decision-making with patients?”

“We’ve seen low doses of aspirin used in the prevention of heart disease and stroke,” said D. Randolph Drosick, M.D., medical oncologist and hematologist with OHC. “Now there are studies showing the potential role for aspirin as a treatment for cancer.”

Peter Elwood, of the Cochrane Institute of Primary Care and Public Health at Cardiff University in the United Kingdom, is the lead and corresponding author of the new analysis, which was published in the journal PLOS One. In 2012, three studies published in the journal The Lancet suggested that a daily intake of aspirin may prevent a series of cancers in middle-aged people. Also, last year, Medical News Today reported on another study that found aspirin enhances the effectiveness of an anti-cancer drug in mice. In this context, Elwood and team set out to examine the benefits of aspirin intake in the treatment of cancer. Their paper is entitled “Systematic review update of observational studies further supports aspirin role in cancer treatment: time to share evidence and decision-making with patients?”

To investigate the role of aspirin in cancer treatment, Elwood and colleagues looked at 71 studies, which summed up over 120,000 people who had been diagnosed with cancer and started taking aspirin in addition to their treatment. Two independent reviewers assessed the eligibility of the studies and examined the number of cancer-related deaths, the incidence of metastases, and the mortality from other causes among people in the aspirin-taking group. The researchers then compared these data with those of approximately 400,000 people who did not take the drug. Of the studies included in the analysis, 29 examined cases of colorectal cancer. In addition, the researchers focused on breast cancer, which featured in 14 studies, and prostate cancer, which was the subject of 16 studies.

Overall, the analysis revealed that the chances of surviving a cancer diagnosis were 20 – 30 percent greater among people who took aspirin compared with those who did not. This was true at any given point after receiving the diagnosis. Elwood and colleagues also note that the evidence suggests aspirin may benefit different cancers to varying extents. Aspirin seems to reduce the risk of dying from colon cancer by 25 percent, breast cancer by 20 percent, and prostate cancer by 15 percent.

Zooming in on colon cancer, for example, one of the studies analyzed revealed that the outlook of an otherwise healthy, 65-year-old man who receives a diagnosis of colon cancer and starts to take aspirin is similar to that of a 60-year-old man who is in the same situation but does not take aspirin.

The authors concede some limitations to their review. For instance, they write that the studies reviewed are purely observational and some of them did not find any benefits to taking aspirin. However, Elwood and colleagues conclude that the findings “merit wide discussion regarding whether or not it is adequate to justify the recommendation of low-dose therapeutic aspirin” in the treatment of cancer.

Evidence from further studies is urgently required, and patients should be strongly encouraged to participate in appropriate research studies said the study’s lead author.

“Although more research is needed, patients with cancer should be aware of these findings and talk with their doctor to determine if they might benefit from a daily low dose of aspirin,” added Dr. Drosick. “I want to stress that patients should discuss this with their doctor and decide together. They shouldn’t just go out, buy aspirin and start taking it. All patients should always talk with their doctor before starting any new medicine.”

OHC (Oncology Hematology Care) has been fighting cancer on the front lines for more than three decades. We are the region’s leading experts in the treatment of nearly every form of adult cancer and complex blood disorder. OHC offers the latest medical, gynecologic and radiation therapy, and is always seeking better treatment options through participation in clinical trials. OHC is certified by the American Society for Clinical Oncology in the Quality Oncology Practice Initiative Certification Program, is an accredited Oncology Medical Home, and is one of only 179 practices nationally to be accepted into the Medicare Oncology Initiative. At its heart, our approach to cancer care is simple – to surround you with everything you need so you can focus on what matters most: beating cancer. For more information about services and careers at OHC, call 1-888-649-4800 or visit ohcare.com.

 
 

Leave a Reply

Your email address will not be published. Required fields are marked *